生物前FeNO可能预测抗IL-5/IL-5Rα对严重喘患者治疗的反应

相关实验视频

Updated: Jun 3, 2025

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples

Published on: January 21, 2018

Bruno Sposato¹, Marco Scalese², Gianna Camiciottoli³

¹Pneumology Department, Azienda USL Toscana Sud-Est, "Misericordia" Hospital, Grosseto, Italy.

The Journal of asthma : official journal of the Association for the Care of Asthma

|January 9, 2025

概括

基线分数呼出的氧化 (FeNO) 水平可以预测严重喘的治疗反应. 较高的FeNO水平 (≥25ppb) 与改善的肺功能和减少与抗IL-5/5R生物药物的口服皮质类固醇使用有关.

科学领域:

呼吸系统医学呼吸系统医学
免疫学免疫学免疫学
生物标志物生物标志物

背景情况:

严重喘管理仍然具有挑战性,生物治疗反应的预测因素有限.
抗干白素-5 (IL-5) 和抗干白素-5受体 (IL-5R) 生物药物对酸性喘有效.
在预测治疗结果方面,基线部分呼出的氧化 (FeNO) 的作用尚未完全确定.

研究的目的:

调查基线FeNO水平是否可以预测在严重喘中对抗IL-5/5R生物药物的治疗反应.
评估FeNO水平对肺功能,临床症状和类固醇节约效应的影响.

主要方法:

分析了一组104名患有严重酸性喘的患者,这些患者接受了抗IL-5/5R生物药物治疗.
患者根据基线FeNO水平 (<25ppb与≥25ppb) 进行了分层.
评估了FEV1,FEF25-75,喘控制测试 (ACT) 分数,恶化和皮质类固醇剂量的变化.

主要成果:

在治疗后,FeNO基线较高 (≥25ppb) 的患者在FEV1% (11.2%对3.34%,p=0.012) 和FEV25-75% (9.6%对2.1%,p=0.05) 中显著改善.
较高比例的FeNO≥25ppb患者减少或停止服用口服皮质类固醇 (94.1%与71.7%相比).
多变量分析证实FeNO≥25ppb作为改善肺功能和减少口服皮质类固醇使用的预测因素.

结论:

基线FeNO水平可以作为在严重的eosinophilic喘中对抗IL-5/5R生物治疗反应的预测生物标志物.
较高的FeNO水平与更好的肺功能改善和更大的类固醇节约效应有关.
FeNO有可能指导治疗选择,以优化严重喘的结果.

关键词:

这就是FeNO FeNO.严重的喘严重的喘这是一种抗IL-5的药物.这是一种抗IL-5Rαα的药物.这就是Benralizumab.生物的生物的生物的生物.这就是Mepolizumab.现实生活中的现实生活.响应响应响应响应

更多相关视频

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

相关概念视频

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Asthma-IV: Diagnostic and Management

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

Asthma-II: Pathophysiology and Classification

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

Asthma: Pathogenesis and Management

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...